Navigation Links
'Tumor Paint' Research Of Pediatric Oncologist Jim Olson Featured In Short Film -- A Sundance Festival Semifinalist
Date:11/27/2012

SEATTLE, Nov. 27, 2012 /PRNewswire/ -- A three-minute film about a tiny molecule that lights up brain tumors so neurosurgeons can better distinguish cancer from normal tissue has a chance to get its own moment in the spotlight as a semifinalist in the Sundance Film Festival in January.

"Bringing Light," (http://vimeo.com/51888804) which focuses on the "Tumor Paint" research led by James Olson, M.D., Ph.D., a clinical researcher at Fred Hutchinson Cancer Research Center and a pediatric oncologist at Seattle Children's Hospital, is available online for viewing and voting. Viewers have until Dec. 20 to cast their votes.

The film, directed by Bert Klasey, Chris Baron and James Allen Smith, also features neurosurgeon Richard Ellenbogen, M.D., chairman of the Department of Neurosurgery at the University of Washington School of Medicine, among others. It is part of a filmmaker competition called "Short Films, Big Ideas" sponsored by Focus Forward Films. Out of 30 total entries, five finalists will be screened at Sundance 2013 and the grand-prize winner will receive $100,000.

Olson's team developed Tumor Paint by re-engineering scorpion venom (chlorotoxin), which naturally targets brain cancer cells, by tagging it with a molecule that acts like a flashlight, causing brain tumors to "light up" during surgery so the margins can be seen more easily. The goal is to help surgeons remove as much cancer as possible while safely leaving normal brain tissue intact.

Tumor Paint is not yet in human use but is being developed by Blaze Bioscience, a Seattle biotech founded by Olson and Heather Franklin, president and CEO.

The potential of Tumor Paint is not limited to brain tumors; it has been found in preclinical studies to light up prostate, colon, breast and other cancers.  It is anticipated that human trials in cancer patients will begin next year.

If the human clinical trial results match the laboratory studies, Tumor Paint will enable surgeons to distinguish cancer tissue from non-cancerous tissue in real time as they operate. The ultimate goal is to save lives while also reducing problems caused by surgical removal of normal tissue in critical areas.

Another potential use for Tumor Paint is early detection of various forms of skin cancer. Olson and colleagues have demonstrated that it can light up non-pigmented skin cancers, which are sometimes difficult to detect and pose a greater threat to the patient if they are not detected early.

Olson gratefully points out that none of this research would have been possible without the support of private donors. "The work on Tumor Paint was funded primarily through financial gifts made to Fred Hutch and Seattle Children's Hospital by individuals, families and businesses that place their trust in our researchers to invent and develop new lifesaving therapies," he said.

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit www.fhcrc.org or follow Fred Hutch on Facebook, Twitter or YouTube.

This news release was issued on behalf of Newswise™. For more information, visit http://www.newswise.com.

Media Contacts:
Kristen Woodward
kwoodwar@fhcrc.org
206-667-5095


'/>"/>
SOURCE Fred Hutchinson Cancer Research Center
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is Expected to Reach USD 7.9 billion by 2018: Transparency Market Research
2. Protein that helps tumor blood vessels mature could make cancer drugs more effective
3. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
4. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
5. First targeted and programmable nanomedicine to show clinical antitumor effects published
6. Novel compound halts tumor spread, improves brain cancer treatment in animal studies
7. bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
8. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
9. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
10. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
11. Nano-infused paint can detect strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016 Research and Markets has ... Sequencing - Technologies, Markets and Companies" to their offering. ... , , ... basics of human genome variations, development of sequencing technologies, and ... well as companies developing them. Various applications of sequencing are ...
(Date:12/4/2016)... Dec. 3, 2016  In five studies being presented ... Annual Meeting and Exposition in San Diego ... to improve the delivery of life-saving treatments to patients ... are designed to carry therapies directly to the sites ... could provide a substantial advantage over traditional, systemic methods. ...
(Date:12/2/2016)... Dec. 2, 2016  The Multiple Myeloma Research Foundation ... MMRF CoMMpass Study SM —the largest and most comprehensive ... in multiple myeloma—will be presented at the 58 th ... Exposition in San Diego from ... treatment strategies, as well as identify pathways and targets ...
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today that it will ... AC0010 at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria ... I/II clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring ...
Breaking Biology Technology:
(Date:6/27/2016)... , June 27, 2016 Research and Markets ... America 2016-2020" report to their offering. ... North America to grow at a CAGR of 12.28% ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
Breaking Biology News(10 mins):